US6491672B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Transurethral volume reduction of the prostate (TUVOR)
Assignee: Magna Powertrain Hueckeswagen GmbH
•
Filing: 2001-02-07
•
Granted: 2002-12-10
•
Expires: 2021-02-07
Abstract
Abstract A process has been developed to reduce or relieve prostatic obstruction. The steps involved in the TUVOR Process include: 1. Transurethral Incision; 2. De-bulking and Intra-Prostatic Volume Reduction; 3. Intra-prostatic void exclusion and space filling with adhesive and/or therapeutic polymeric materials, alone or in combination with bioactive agents and/or mechanical means for closure; 4. Endourethral compression and prostatic mass remolding; 5. Endourethral Polymer Liner Layer. This liner formed from structurally supportive, yet eventually biodegradable, polymers further bolsters and supports the urethra and peri-urethral tissue during healing, eliminating the need for post-procedure catheter drainage. This step may be optional in specific clinical circumstances. The process is designed to allow outpatient treatment under local anesthesia for BPH.
Inventors
- 👤 Marvin J. Slepian
- 👤 Daniel Yachia
- 👤 Syed Hossainy
- 👤 Baruch Levy
- 👤 Zeev Sohn
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:33
CPC Classifications
A; A61; A61B; A61B17/00; A61B17/32; A61B17/3205; A61B17/3207; A61B17/320758; A61B17/320725; A61B17/00491; A61B17/00234; A61B2017/00238; A61B2017/00274; A61B2017/00535; A61B2017/00557; A61B17/22; A61B2017/22072; A61B17/34; A61B17/3417; A61B17/3421; A61B2017/3445; A61B18/00; A61B2018/00315; A61B2018/00547; A61B90/00; A61B90/36; A61B90/361
Claims Analysis
Total Claims: 43
Claim 1
Independent Claim
65 words
A method for treating prostate disease comprising: making an incision into the prostate, reducing the volume of the prostate by removing endomural tissue to form at least one void in the prostate, and closing the voids in the prostate, wherein an adhesive material is applied within the void prior to closure or a supportive material is applied to the urethra lining to provide structural support.
Claim 2
Independent Claim
65 words
A method for treating prostate disease comprising: making an incision into the prostate, reducing the volume of the prostate by removing endomural tissue to form at least one void in the prostate, and closing the voids in the prostate, wherein an adhesive material is applied within the void prior to closure or a supportive material is applied to the urethra lining to provide structural support.
Claim 3
Dependent Claim
17 words
The method of claim 1 comprising applying an adhesive biodegradable material within the voids prior to closure.
Claim 4
Dependent Claim
21 words
The method of claim 2 wherein the adhesive biodegradable material is sufficient to effect closure of the voids until healing occurs.
Claim 5
Dependent Claim
13 words
The method of claim 1 wherein the voids are closed by mechanical means.
Claim 6
Dependent Claim
17 words
The method of claim 4 wherein the voids are closed using a balloon catheter within the urethra.
Claim 7
Dependent Claim
12 words
The method of claim 1 wherein the incision is a transurethral incision.
Claim 8
Dependent Claim
13 words
The method of claim 1 wherein multiple voids are created in the prostate.
Claim 9
Dependent Claim
31 words
The method of claim 1 wherein the incision and tissue removal is effected using a cutter device positioned within a catheter that can be passed into the urethra to the prostate.
Claim 10
Dependent Claim
18 words
The method of claim 1 further comprising administering bioactive agents to the urethra or voids within the prostate.
Claim 11
Dependent Claim
24 words
The method of claim 9 wherein the bioactive agents are selected from the group consisting of drugs, genes, cells, and molecules altering cellular adhesion.
Claim 12
Dependent Claim
44 words
The method of claim 10 wherein the drugs are selected from the group consisting of antibiotics, antivirals, antiinflammatories, hormones, antineoplastics, anti-spasmodics, modulators of cell-extracellular matrix interactions, enzymes, enzyme inhibitors, anticoagulants, growth factors, DNA, RNA and protein synthesis inhibitors, anti-cell migratory agents, and vasodilating agents.
Claim 13
Dependent Claim
19 words
The method of claim 11 wherein the drugs are selected from the group consisting of hormones and chemotherapeutic agents.
Claim 14
Dependent Claim
25 words
The method of claim 1 wherein the material applied to the urethra lining provides structural support sufficient to allow flow of urine through the urethra.
Claim 15
Dependent Claim
17 words
The method of claim 1 wherein material applied to the voids or urethra lining is a polymer.
Claim 16
Dependent Claim
12 words
The method of claim 14 wherein the polymer is a biodegradable polymer.
Claim 17
Dependent Claim
20 words
The method of claim 15 wherein the polymer is conformable by a change in temperature or mechanical forces in situ.
Claim 18
Dependent Claim
22 words
The method of claim 15 wherein the polymer is applied in a fluent state and converted in situ to a non-fluent state.
Claim 19
Dependent Claim
17 words
The method of claim 17 wherein the polymer is polymerized in situ by application of a stimulus.
Claim 20
Dependent Claim
23 words
The method of claim 18 wherein the stimulus is light, temperature change, exposure to ions, addition of a catalyst or initiator, or radiation.
Claim 21
Dependent Claim
11 words
The method of claim 1 further comprising mechanically compressing the voids.
Claim 22
Dependent Claim
19 words
The method of claim 20 wherein the voids are compressed by expansion of a balloon catheter in the urethra.
Claim 23
Dependent Claim
11 words
The method of claim 21 further comprising mechanically closing the voids.
Claim 24
Dependent Claim
132 words
A kit for treating prostate disease comprising making an incision into the prostate, reducing the volume of the prostate by removing endomural tissue to form at least one void in the prostate, and closing the voids in the prostate, wherein an adhesive material is applied within the void prior to closure or a supportive material is applied to the urethra lining to provide structural support, comprising a catheter suitable for insertion into the urethra comprising means for making a transurethral incision, means for cutting and morselating tissue, one or more lumens for administration of an adhesive material or a supportive material to the urethra, means for removal of morselated tissue, and a biocompatible, biodegradable material suitable for administration within the prostate to adhere tissue or within the urethral to provide structural support.
Claim 25
Dependent Claim
132 words
A kit for treating prostate disease comprising making an incision into the prostate, reducing the volume of the prostate by removing endomural tissue to form at least one void in the prostate, and closing the voids in the prostate, wherein an adhesive material is applied within the void prior to closure or a supportive material is applied to the urethra lining to provide structural support, comprising a catheter suitable for insertion into the urethra comprising means for making a transurethral incision, means for cutting and morselating tissue, one or more lumens for administration of an adhesive material or a supportive material to the urethra, means for removal of morselated tissue, and a biocompatible, biodegradable material suitable for administration within the prostate to adhere tissue or within the urethral to provide structural support.
Claim 26
Dependent Claim
21 words
The kit of claim 23 wherein the biocompatible, biodegradable material is a solution forming an adhesive polymer in situ following application.
Claim 27
Dependent Claim
23 words
The kit of claim 23 wherein the biocompatible, biodegradable material is a solution forming a structurally supportive lining in the urethra following application.
Claim 28
Dependent Claim
33 words
The kit of claim 23 wherein the biocompatible, biodegradable material is a conformable solid that can be inserted into the urethra and conformed to the surface to form a barrier or support structure.
Claim 29
Dependent Claim
19 words
The kit of claim 23 further comprising bioactive agents for administration to the urethra or voids within the prostate.
Claim 30
Dependent Claim
24 words
The kit of claim 27 wherein the bioactive agents are selected from the group consisting of drugs, genes, cells, and molecules altering cellular adhesion.
Claim 31
Dependent Claim
44 words
The kit of claim 28 wherein the drugs are selected from the group consisting of antibiotics, antivirals, antiinflammatories, hormones, antineoplastics, anti-spasmodics, modulators of cell-extracellular matrix interactions, enzymes, enzyme inhibitors, anticoagulants, growth factors, DNA, RNA and protein synthesis inhibitors, anti-cell migratory agents, and vasodilating agents.
Claim 32
Dependent Claim
19 words
The kit of claim 29 wherein the drugs are selected from the group consisting of hormones and chemotherapeutic agents.
Claim 33
Dependent Claim
17 words
The kit of claim 23 wherein material applied to the voids or urethra lining is a polymer.
Claim 34
Dependent Claim
12 words
The kit of claim 31 wherein the polymer is a biodegradable polymer.
Claim 35
Dependent Claim
20 words
The kit of claim 32 wherein the polymer is conformable by a change in temperature or mechanical forces in situ.
Claim 36
Dependent Claim
22 words
The kit of claim 32 wherein the polymer is in a fluent state which is convertable in situ to a non-fluent state.
Claim 37
Dependent Claim
17 words
The kit of claim 34 wherein the polymer is polymerized in situ by application of a stimulus.
Claim 38
Dependent Claim
23 words
The kit of claim 35 wherein the stimulus is light, temperature change, exposure to ions, addition of a catalyst or initiator, or radiation.
Claim 39
Dependent Claim
12 words
The kit of claim 23 wherein the catheter further comprises expansion means.
Claim 40
Dependent Claim
15 words
The kit of claim 37 wherein the catheter further comprises means for suturing or stapling.
Claim 41
Dependent Claim
24 words
The kit of claim 23 wherein the catheter further comprises means for generating light, radiation or a temperature change in the voids or urethra.
Claim 42
Dependent Claim
18 words
The kit of claim 23 wherein the catheter further comprises means for conforming a lining within the urethra.
Claim 43
Dependent Claim
14 words
The kit of claim 23 wherein the catheter further comprises suction or vacuum means.
References Cited (Backward Citations)
US2677700A
Cited
US2675619A
Cited
US2979578A
Cited
US3306118A
Cited
US3535307A
Cited
US3829506A
Cited
US4228802A
Cited
US5041380A
Cited
US4517686A
Cited
US4578079A
Cited
US4589881A
Cited
US4938763A
Cited
US5149780A
Cited
US4938763B1
Cited
US5169930A
Cited
US5762626A
Cited
US5807309A
Cited
EP0893101A2
Cited
US5792157A
Cited
US5794626A
Cited
DE19706751A1
Cited
DE19703208A1
Cited
US6206900B1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2005-12-09 | 2006-06-10 | 2006-12-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2009-12-09 | 2010-06-10 | 2010-12-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2013-12-09 | 2014-06-10 | 2014-12-10 | $7700.00 | Window Closed / Lapsed |